KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Free Cash Flow (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed Free Cash Flow for 18 consecutive years, with -$814.6 million as the latest value for Q1 2026.

  • For Q1 2026, Free Cash Flow fell 398.67% year-over-year to -$814.6 million; the TTM value through Mar 2026 reached -$971.3 million, down 90.14%, while the annual FY2025 figure was -$320.0 million, 36.24% up from the prior year.
  • Free Cash Flow hit -$814.6 million in Q1 2026 for Ionis Pharmaceuticals, down from -$159.0 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $139.0 million in Q2 2025 and bottomed at -$814.6 million in Q1 2026.
  • Average Free Cash Flow over 5 years is -$131.4 million, with a median of -$124.0 million recorded in 2024.
  • Year-over-year, Free Cash Flow plummeted 410.36% in 2023 and then skyrocketed 210.24% in 2025.
  • Ionis Pharmaceuticals' Free Cash Flow stood at -$204.3 million in 2022, then skyrocketed by 128.05% to $57.3 million in 2023, then tumbled by 269.76% to -$97.3 million in 2024, then tumbled by 63.41% to -$159.0 million in 2025, then crashed by 412.31% to -$814.6 million in 2026.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$814.6 million, -$159.0 million, and -$136.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.